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Abstract
Background: There have been limited numbers of studies on patients with chronic kidney disease (CKD) to determine 
oxidative stress in exhaled breath condensate (EBC). Those two studies have been carried out on hemodialysis patients, 
and hydrogen peroxide and nitric oxide have been studied in order to show oxidative stress on EBC.
Aims: We investigated oxidative stress in EBC evaluating 8‑isoprostane levels on different stages of CKD.
Materials and Methods: A total of 81 patients with 2‑4 CKD stages have been evaluated prospectively. The patients 
have been categorized into three groups according to their CKD stages. For biochemical analysis, blood and breathing 
air samples were taken. 8‑isoprostane has been measured using immunoassay method as the indicator of oxidative 
stress in EBC.
Results: 8‑isoprostane values were 8.19 ± 4.56, 13.89 ± 8.70, and 14.20 ± 10.68 pg/min group 1, 2, and 3, respectively; 
and the EBC 8‑isoprostane levels increased significantly as CKD stages advanced (P = 0.018). There was a statistically 
significant reverse correlation between 8‑isoprostane and glomerular filtration rate (GFR; r = −0.275; P = 0.014), but 
not between 8‑isoprostane and C‑reactive protein (r = −0.183; P = 0.177).
Conclusions: We determined the level of 8‑isoprostane in EBC of patients with different stages of CKD and showed 
that the level of 8‑isoprostane significantly increased through the progress of CKD. We consider that our study is 
important because there have been limited number of studies that evaluate oxidative stress in CKD using EBC which 
is a noninvasive method.
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Introduction
Chronic kidney disease (CKD) is a chronic, progressive 
disease presenting with irreversible renal damage depending 
upon reduction at glomerular filtration rate (GFR) and 
is a major cause of morbidity and mortality around the 
world.[1] Various mechanisms such as uncontrolled blood 
pressure, dyslipidemia, insulin resistance (IR), proteinuria, 
and oxidative stress (OS) have been suggested to express 
the progressive loss of function.[2,3]
The normal intracellular balance between reactive oxygen 
species (ROS) produced during aerobic metabolism and 
antioxidant defense mechanisms performing the function 
of free radical inactivation were modified by OS. The 
upregulation of OS mainly occurring during increased flux 
of free radicals/ROS and/or reduced antioxidant levels has 
now been accepted to play a critical role in the pathogenesis 
of obesity, atherosclerosis, type‑2 diabetes mellitus (T2DM), 
and IR.[4,5] The antioxidant system has been reported to 
decrease and OS to increase with CKD progression in 
studies that have been carried out before.[6,7] Due to several 
clinical conditions, various oxidants can increase in serum 
or tissues. 8‑isoprostane, a stable prostaglandin‑like product, 
is formed from arachidonic acid by the nonenzymatic action 
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of ROS, and therefore, it has been suggested to be a marker 
of OS and oxidative activities.[8] In a study evaluating OS 
in CKD patients with 8‑isoprostane, an inverse correlation 
was found between GFR and OS.[7]
Exhaled breath condensate (EBC) is a noninvasive 
method used for taking a sample from lungs in order to 
measure several biological indicators.[9] There have been 
limited number of studies that studied OS in CKD on 
EBC.[10,11] Those two studies have been carried out on 
hemodialysis patients, and hydrogen peroxide (H2O2) and 
nitric oxide (NO) have been studied in order to shown OS 
on EBC. Unlike those studies, we have searched for OS 




A total of 81 CKD patients over 18‑years‑old who had 
GFR values between 15 and 90 ml/min were evaluated 
prospectively between October 2010 and February 
2011. All of the patients were consecutive and recruited 
from Department of Internal Medicine and Nephrology 
outpatient clinics at Gaziosmanpasa University. The 
patients with GFR < 15 ml/min, GFR > 90 ml/min, active 
infection symptom and finding, diabetes mellitus diagnosis, 
history of malignity, asthma or chronic obstructive lung 
disease (COPD), allergic rhinitis, smoking, gastroesophageal 
reflux symptoms, diseases requiring anti‑inflammatory 
treatment, and the ones using antioxidant drugs were 
all excluded from the study. GFR values of the patients 
were measured with MDRD (The Modification of Diet 
in Renal Disease) formula, and according to National 
Kidney Foundation guidelines. The patients who had 
GFR = 60‑89 ml/min were categorized as group 1 
(stage 2), GFR = 30‑59 ml/min as group 2 (stage 3), and 
GFR = 15‑29 ml/min as group 3 (stage 4).[1]
Blood pressure was measured using a calibrated aneroid 
sphygmomanometer. Hypertension (HT) was defined as 
systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood 
pressure (DBP) ≥ 80 mmHg and/or use of antihypertensive 
medications.[12] The body mass index (BMI) was calculated 
from the measured weight (in kilograms) and height 
(in meters). Demographic parameters of the patients such 
as age and gender were recorded. For the analysis, blood and 
breathing air samples were collected. The study protocol 
was approved by the local ethics committees and informed 
consent was obtained from all the participants.
Measurement of 8‑isoprostane in exhaled breath 
condensate
EBC was collected from the patients in each group using 
a condensing device (Ecoscreen, Jaeger, Germany). The 
samples were taken through nose‑clip method model putting 
a saliva trap within the condenser. Patients were asked to 
breathe out spontaneously through a mouthpiece equipped 
with a saliva trap for 5‑15 min. Amylase level that was 
normally controlled routinely for salivary contamination was 
controlled due to the use of salivary filter and disallowance 
to the salivary contamination. The liquid formed as result 
of the condensation of respiratory air was collected; the 
collected liquid was split into tubes in 600 µl pieces and 
stored at ‑80°C until measurement. The collection of EBC 
was performed following available recommendations.[9] All 
EBC samples were collected at the same time of day, between 
2.00 and 3.00 PM. Samples were stored for 2 months and 
analyzed at the same time. 8‑isoprostane as the indicator 
of OS was measured through enzyme immunoassay using 
Cayman Chemical 8‑isoprostane kits. The detection limit 
was 2.7 pg/ml.
Serum samples were taken from the patients for analysis 
of chemical parameters including triglyceride (TG), 
high density lipoprotein‑cholesterol (HDL‑C), and 
C‑reactive protein (CRP) levels. Serum HDL‑C and TG 
were determined enzymatically (Olympus Diagnostica, 
Lismeehan, Ireland). For all laboratory parameters, venous 
blood samples were taken between 8.00 and 9.00 AM 
following 12‑hour fasting.
Statistical analyses
All statistical analyses were conducted using Statistical 
Package for Social Sciences (SPSS) 12 software. Analysis of 
variance (ANOVA) method was used in order to determine 
whether there was difference among the three groups 
or not. The ANOVA table was analyzed to determine 
whether or not those differences were random. Bonferroni 
test was performed to see among which groups there were 
differences. Descriptive statistics of the all parameters in 
the study were measured. All variables were checked for 
their normality and the variables distributed normally. The 
data were transformed and because transformed data did 
not distribute normally, use of nonparametric statistical 
method were decided using original data. Then, Spearman’s 
rho correlation was used in order to find the relationships 
between 8‑isoprostane value and other variables and 
the degrees of relationships. The value of P < 0.05 was 
considered significant.
Results
The average age of the 81 patients included into the 
study was 56 ± 15. Forty of the patients were female and 
41 male. The patients were classified into three equal 
groups according to CKD stages 2, 3, and 4. The group 1 
(average age 57 ± 12 years; 15 females and 12 males), 
group 2 (average age 56 ± 16 years; 10 females and 
17 males), and group 3 (average age 55 ± 17 years; 
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15 females and 12 males) included 27 patients each. The 
groups were concordant in terms of age and gender.
BMI was 27.17 ± 4.69 kg/m2 in group 1, 27.13 ± 5.08 kg/m2 
in group 2, and 26.22 ± 5.72 kg/m2 in group 3. There were 
no statistically significant differences among the groups 
in terms of body weight (P = 0.742). About 85% of the 
patients were hypertensive. There was HT in 81.48% 
(n = 22) of the patients in group 1, in 85.18% (n = 23) 
in group 2, and in 88.88% (n = 24) in group 3. Average 
SBP/DBP of the was 136 ± 22/84 ± 12 mmHg in 
group 1, 136 ± 25/81 ± 13 mmHg in group 2, and 
146 ± 29/87 ± 15 mmHg in group 3. No difference was 
observed among the groups in terms of SBP (P = 0.264) 
and DBP (P = 0.274).
Serum, GFR, low density lipoprotein (LDL), HDL, TG, CRP, 
and 8‑isoprostane levels of the groups were given in Table 1. 
There were no significant differences among the groups in 
terms of LDL, HDL, TG, and CRP values. There were no 
differences between the groups in terms of the drugs such 
as angiotensin‑converting enzyme inhibitors, angiotensin 
receptor blockers, and statins used for the treatment of HT 
and hyperlipidemia.
8‑isoprostane values were 8.19 ± 4.56, 13.89 ± 8.70, 
and 14.20 ± 10.68 pg/min group 1, 2, and 3, respectively, 
and the EBC 8‑isoprostane levels increased significantly 
as CKD stages advanced (P = 0.018). The 8‑isoprostane 
levels in groups 2 and 3 were significantly higher than that 
in group 1 (P = 0.047 and 0.035). 8‑isoprostane level of 
group 3 was higher than that of group 2, but this difference 
was not significance (P = 0.99) [Figure 1].
A significant inverse correlation was found between 
8‑isoprostane and GFR (r = −0.275; P = 0.014), but not 
between 8‑isoprostane and CRP (r = −0.183; P = 0.177).
Discussion
In relation to renal parenchymal damage and decreased 
GFR, presence of OS in CKD depends upon the increases 
in the level of oxidation in plasma and tissues, decreases 
in antioxidant capacity, and deterioration of antioxidant 
enzymes.[13] Increase of OS in CKD has been shown in some 
studies.[6,7,14,15] In a study carried out by Nagane et al.,[6] on 
different phases of CKD to prove OS, investigators proved 
that superoxide dismutase and nitric oxide (NO) significantly 
decrease and malondialdehyde and homocysteine 
significantly increase compared to the control group in 
CKD patients separated into five stages. This study revealed 
that antioxidant system weakens and OS increases with the 
progression of CKD. In their study, Oberg et al.,[15] have 
specified that several inflammations and OS biomarkers 
in blood samples of 60 patients having stage 3‑5 CKD 
were higher than the healthy people. However, there was 
no signifcant relationship between GFR and any OS or 
infammation biomarker. In another study which included 
87 patients with 1‑4 phases CKD, plasma 8‑isoprostane 
levels were measured. It was found that as the CKD phases 
progress, plasma 8‑isoprostane levels significantly increase. 
A significant inverse correlation was also observed between 
GFR and plasma 8‑isoprostane. OS was shown to increase 
with CKD progression and to have significant correlation 
with reduced kidney function.[7] Similarly, in present study 
8‑isoprostaten was used to evaluate of OS in different stages 
of CKD. However, in contrast to other studies, in our study, 
OS was evaluated in EBC which is known noninvasive 
method. In addition, it was detected that 8‑isoprostane level 
significantly increased as the phase of CKD has progressed.
Majority of the studies carried out to evaluate OS in CKD 
were the ones in which OS indicators were measured in 
blood samples. EBC is a noninvasive method used for taking 
samples from the lungs in order to measure several biological 
indicators.[9] 8‑isoprostane is one of the reliable indicators 
of OS. 8‑isoprostane is an isomer of prostaglandin F2 
alpha (PGF2a) and it is formed by a dominant nonenzymatic 
reaction from arachidonic acid peroxidation as result of the 
catalization of free radicals. It is chemically stabile, specific 








GFR (ml/min) 70.39±7.35 43.84±7.22 21.33±4.85 *
8‑isoprostane 
(pg/ml)
8.19±4.56 13.89±8.70 14.20±10,68 0.018
CRP (mg/L) 13.98±22.45 9.08±12.10 7.21±6.43 0.376
LDL (mg/dl) 132.66±38.01 125.48±47.13 117.38±35.30 0.404
HDL (mg/dl) 53.24±20,58 46.25±9.70 48.62±11.19 0.241
TG (mg/dl) 157.60±59.18 160.58±94.17 149.69±67.28 0.867
*The statistical analysis was not performed. GFR=Glomerular filtration 
rate, CRP=C‑reactive protein, LDL=Low density lipoprotein, HDL=High 
density lipoprotein, TG=Triglyceride
Figure 1: Mean exhaled breath condensate 8‑isoprostane 
levels in the chronic kidney disease stages 2‑4 (analysis of 
variance, P=0.018) (a) Average EBC 8‑isoprostane levels in the 
groups (ANOVA P=0.018)
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for lipid peroxidation, and has been suggested to be a marker 
of oxidative activities and oxidative stress.[16] There have 
been studies showing that 8‑isoprostane level increases in 
EBC in some diseases such as COPD, asthma, interstitial 
lung disease, pulmonary sarcoidosis, obstructive sleep 
apnea syndrome and cystic fibrosis.[17‑22] We also studied 
8‑isoprostane a chemically stabile indicator of OS. There 
have been limited number (two) of studies that evaluate 
OS in CKD with EBC.[10,11] Rysz et al.,[10] have compared 
H2O2 level in EBC of 29 chronic hemodialysis (HD) patients 
and 40 healthy people. They found significantly higher 
H2O2 levels in patient group compared to the control 
group. Rolla et al.,[11] have studied NO and NO metabolites 
with EBC in 12 chronic HD patients and suggested that 
oxidative stress was the most probable cause of increased 
NO metabolites in end stage renal disease patients before 
HD. Those two studies are the ones carried out with chronic 
HD patients. The present study is the first to evaluate OS in 
different stages of CKD as measured by EBC 8‑isoprostane.
It has been shown that reactive oxygen production increase 
along with the age. OS increases as a result of oxidative 
phosphorylation change and mitochondrial DNA damage.[23] 
In a study in which the relationship of essential HT and OS 
was researched, it was determined that high blood pressure 
had negative correlation with antioxidant level of the plasma 
and 8‑isoprostane measured in the plasma and urinary had 
a positive correlation with the blood pressure.[24] Moreover, 
some other studies have reported that obesity, IR, and 
hyperlipidemia were correlated with OS.[25‑27] In our study, 
age, blood pressure, BMI, and lipid values were similar among 
the groups, revealing the absence of any association between 
them and OS in different CKD stages.
There are some limitations of this current study. Differences 
in procedures such as collection, storage, and analysis of 
the samples affect 8‑isoprostane levels. The same technical 
analysis was used to carry out all procedures by the 
experienced personnel for eliminating these aforementioned 
differences. So as to eliminate the diurnal rhythm effect, 
samples were taken at the same time intervals of the day. In 
addition, a many diseases and drugs may negatively effect on 
8‑isoprostane levels. Therefore, in patient selection, some 
disorders such as COPD, asthma and antioxidant usage 
were excluded from the study.
Conclusion 
In conclusion, in the present study we showed that 
8‑isoprostane level as an indicator of OS significantly 
increased in patient groups in different phases of CKD and 
that as the CKD stage progressed, the level of 8‑isoprostane 
significantly increased. We consider that our study is 
important because it is one of the limited number of studies 
that evaluate OS in CKD with noninvasive EBC method 
and because it is the first study to evaluate OS on different 
stages of CKD using this method.
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